


AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

1. (Currently amended) A compound of Formula (I):



(I)

or a salt, ~~or solvate, or physiologically functional derivative thereof:~~
wherein

A is the group defined by $(Q^3)-(Q^2)_n-(Q^1)-(Q)_m$, wherein

Q is CH_2 and m is 0, 1, or 2

Q^1 is C_3 - C_7 cycloalkylene;


Q^2 is C_1 - C_3 alkylene and n is 0 or 1, or

Q^2 is OR, where R is C_1 - C_3 alkylene and n is 1,

Q^2 is SR, where R is C_1 - C_3 alkylene and n is 1; or

Q^2 is $N(R')R$, where R' is hydrogen or C_1 - C_6 alkyl, R is C_1 - C_3 alkylene and n is 1; and

Q^3 is aryl, heteroaryl, or aryl or heteroaryl substituted with at least one independently selected R^1 group, wherein said heteroaryl is selected from the group consisting of




D is C₁-C₆ alkyl or C₁-C₆ alkyl substituted with -NR²R³;

Z is the group defined by -(X)_p-(X¹)_q-(X²), wherein

X is C(R')(R''), wherein R' is hydrogen or C₁-C₆ alkyl, R'' is hydrogen and C₁-C₆ alkyl, and p is 0, 1, or 2,

X¹ is C(O)OCH₂, wherein q is 0 or 1, and

X² is aryl, heteroaryl, or heterocyclyl wherein said heteroaryl or heterocyclyl is selected from:



R¹ is halo, C₁-C₆ alkyl, aryl, ~~heterocyclyl~~, or C₁-C₆ haloalkyl;

R² is hydrogen or C₁-C₆ alkyl;

R³ is hydrogen, C₁-C₆ alkyl, -C(O)R⁴, or -S(O)₂NR⁵R⁶;

R⁴ is ~~heterocyclyl~~, -NR⁵R⁶, and

R⁵ and R⁶ are independently selected from hydrogen or C₁-C₆ alkyl.

2. (Cancelled)

3. (Cancelled)

4. (Cancelled)

5. (Original) A compound as claimed in claim 1, wherein Q is CH₂ and m is 0, 1, or 2.
6. (Original) A compound as claimed in claim 1, wherein Q is CH₂ and m is 0 or 1.
7. (Original) A compound as claimed in claim 1, wherein Q is CH₂ and m is 1.
8. (Original) A compound as claimed in claim 1, wherein Q¹ is C₃-C₇ cycloalkylene.
9. (Original) A compound as claimed in claim 1, wherein Q¹ is selected from the group cyclobutylene, cyclopentylene or cyclohexylene,
10. (Original) A compound as claimed in claim 1, wherein Q¹ is cyclobutylene.
11. (Original) A compound as claimed in claim 1, wherein Q² is C₁-C₃ alkylene and n is 0 or 1.
12. (Original) A compound as claimed in claim 1, wherein Q² is C₁-C₃ alkylene and n is 1.
13. (Original) A compound as claimed in claim 1, wherein Q² is OR, wherein R is C₁-C₃ alkylene and n is 1.
14. (Original) A compound as claimed in claim 1, wherein Q² is SR, wherein R is C₁-C₃ alkylene and n is 1.
15. (Original) A compound as claimed in claim 1, wherein Q³ is aryl or aryl substituted with at least one independently selected R¹ group.

16. (Original) A compound as claimed in claim 1, wherein Q^3 is phenyl or phenyl substituted with at least one independently selected R^1 group wherein R^1 is halo or C_1 - C_6 alkyl.


17. (Original) A compound as claimed in claim 16, wherein R^1 is halo.

18. (Cancelled)

19. (Original) A compound as claimed in claim 16, wherein R^1 is C_1 - C_6 alkyl.

20. (Cancelled)

21. (Currently amended) A compound as claimed in claim 1, wherein Q^3 is heteroaryl or heteroaryl substituted with at least one independently selected R^1 , wherein said heteroaryl is selected from the group consisting of



22-27 . (Cancelled)

28. (Original) A compound as claimed in claim 1, wherein D is C_1 - C_6 alkyl.

29. (Original) A compound as claimed in claim 1, wherein D is n-butyl.

30-33 (Cancelled)

34. (Original) A compound as claimed in claim 1, wherein X is C(H)(R'') where R'' is hydrogen and p is 0, 1, or 2.

35. (Original) A compound as claimed in claim 1, wherein X is C(R')(R'') where R'' is hydrogen and p is 0, 1, or 2.

36. (Original) A compound as claimed in claim 1, wherein X is C(H)(R'') where R'' is hydrogen and p is 0 or 1.

37. (Original) A compound as claimed in claim 1, wherein X is C(H)(R'') where R'' is hydrogen and p is 0.


38. (Original) A compound as claimed in claim 1, wherein X is C(H)(R'') where R'' is -CH₃ and p is 1.

39. (Original) A compound as claimed in claim 1, wherein X¹ is C(O)OCH₂, wherein q is 1.

40. (Original) A compound as claimed in claim 1, wherein X¹ is C(O)OCH₂, wherein q is 0.


41. (Original) A compound as claimed in claim 1, wherein X² is aryl.

42. (Original) A compound as claimed in claim 1, wherein X² is



43. (Cancelled)

44. (Original) A compound as claimed in claim 1, wherein X² is selected from the group



, or substituted derivatives thereof.

45. (Currently amended) A compound selected from the group consisting of:

1-benzylcyclobutyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

1-benzylcyclopentyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

benzyl(2S)-2-[(3S)-3-([(1-benzylcyclopentyl)oxy]carbonyl)amino]-2-oxoheptanoyl]amino}propanoate;

1-benzylcyclohexyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(1-Benzylcyclobutyl)methyl(1S)-1-(oxo{[(1R)-1-phenylethyl]amino} acetyl) pentyl carbamate;

[1-(2-Phenylethyl)cyclobutyl]methyl (1S)-1-(oxo{[(1R)-1-phenylethyl] amino} acetyl) pentylcarbamate;

[1-(3-Phenylpropyl)cyclobutyl]methyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino} acetyl) pentylcarbamate;

(1-Benzylcyclopentyl)methyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl) pentyl carbamate;

~~(1-benzylcyclohexyl)methyl(1S)-5-[(4-morpholinylcarbonyl)amino]-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;~~

~~[1-(4-Fluorobenzyl)cyclobutyl]methyl (1S)-5-[(4-morpholinylcarbonyl)amino]-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;~~

~~[1-(4-Pyridinylmethyl)cyclobutyl]methyl (1S)-5-[(4-morpholinylcarbonyl)amino]-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;~~

~~[1-(3-pyridinylmethyl)cyclobutyl]methyl (1S)-5-[(4-morpholinylcarbonyl)amino]-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;~~

[1-(2,6-difluorobenzyl)cyclobutyl]methyl (1S)-5-[[[(methylamino)carbonyl]amino]-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

[1-(4-Fluorobenzyl)cyclobutyl]methyl (1S)-1-[oxo(1H-pyrazol-5-ylamino)acetyl]pentylcarbamate;

[1-(4-fluorobenzyl)cyclobutyl]methyl (1S)-1-[[[(6-chloro-1H-indazol-3-yl)amino](oxo)acetyl]pentylcarbamate;

[1-(4-fluorobenzyl)cyclobutyl]methyl (1S)-5-[[[(dimethylamino)sulfonyl]amino]-1-{oxo[(3-pyridinylmethyl)amino]acetyl}pentylcarbamate;

1-(1,3-Benzothiazol-2-yl)cyclopentyl (1S)-1-[oxo(1H-pyrazol-3-ylamino)acetyl]pentylcarbamate;

{1-[(4-phenyl-1,3-thiazol-2-yl)methyl]cyclobutyl}methyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(1-[[[(1-methyl-1H-imidazol-2-yl)sulfonyl]methyl]cyclobutyl]methyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(1-[[[(2-chloro-4-pyrimidinyl)oxy]methyl]cyclobutyl]methyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

[1-(((2-(4-methyl-1-piperazinyl)-4-pyrimidinyl)oxy)methyl)cyclobutyl]methyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

[1-(((2-(4-morpholinyl)-4-pyrimidinyl)oxy)methyl)cyclobutyl]methyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

{1-[(2-pyrimidinylsulfonyl)methyl]cyclobutyl}methyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

{1-[(1,3-benzoxazol-2-ylsulfonyl)methyl]cyclobutyl}methyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

{1-[(1,3-thiazol-2-yl)oxy]methyl]cyclobutyl}methyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(1-[[[(3-phenyl-1,2,4-thiadiazol-5-yl)oxy]methyl]cyclobutyl]methyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

[1-(((2-(4-phenyl-1-piperazinyl)-4-pyrimidinyl)oxy)methyl)cyclobutyl]methyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

(1-(((1-phenyl-1H-imidazol-2-yl)sulfanyl)methyl)cyclobutyl)methyl (1S)-1-(oxo
{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

~~{1-[(thieno[3,2-d]pyrimidin-4-yloxy)methyl]cyclobutyl)methyl (1S)-1-(oxo{[(1R)-1-
phenylethyl]amino}acetyl)pentylcarbamate;~~

~~{1-[(2-pyrimidinylloxy)methyl]cyclobutyl)methyl (1S)-1-(oxo{[(1R)-1-
phenylethyl]amino}acetyl)pentylcarbamate;~~

[1-(((4-(4-methylphenyl)-1,3-thiazol-2-yl)oxy)methyl)cyclobutyl)methyl (1S)-1-
(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

~~{1-(hydroxymethyl)cyclobutyl)methyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}
acetyl)pentylcarbamate;~~

~~{1-(((4-(4-chlorophenyl)-2-pyrimidinyl)sulfanyl)methyl)cyclobutyl)methyl (1S)-1-
(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;~~

[1-(((5-(4-chlorophenyl)-1-methyl-1H-imidazol-2-yl)sulfanyl)methyl)cyclobutyl]
methyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate;

{1-[(4-methyl-1,3-thiazol-2-yl)methyl]cyclobutyl)methyl (1S)-1-(oxo{[(1R)-1-
phenylethyl]amino}acetyl)pentylcarbamate;

(1-{2-[(1-methyl-1H-imidazol-2-yl)sulfanyl]ethyl}cyclobutyl)methyl (1S)-1-
(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate; and

(1-{3-[(1-methyl-1H-imidazol-2-yl)sulfanyl]propyl}cyclobutyl)methyl (1S)-1-
(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate; and

~~(1-{3-[(2-chloro-4-pyrimidinyl)oxy]propyl}cyclobutyl)methyl (1S)-1-(oxo{[(1R)-1-
phenylethyl]amino}acetyl)pentylcarbamate;~~

or a salt, or solvate, or physiologically functional derivative thereof.

46. (Currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound as claimed in claim 1 or a salt, or solvate, ~~or a physiologically functional derivative thereof~~ and one or more of pharmaceutically acceptable carriers, diluents and excipients.

47. (Currently amended) A method of treating a disorder in a mammal, said disorder being characterized by enhanced bone turnover which can ultimately lead

to fracture, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in claim 1 or a salt, or solvate ~~or a physiologically functional derivative thereof~~.

48. (Currently amended) A method of treating a disorder in a mammal, said disorder being characterized by bone loss, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in claim 1 or a salt, or solvate ~~or a physiologically functional derivative thereof~~.

49-50. (Cancelled)

51. (Currently amended) A method of treating osteoporosis, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in claim 1 or a salt, or solvate ~~or a physiologically functional derivative thereof~~.

52. (Currently amended) A method of treating osteoporosis, comprising: administering to said mammal therapeutically effective amounts of (i) a compound as claimed in claim 1, or a salt, or solvate ~~or a physiologically functional derivative thereof~~ and (ii) at least one bone building agent.